04.05.06
HollisterStier Contract Manufacturing has signed a Letter of Intent with Prism Pharmaceuticals to develop a process for compounding and fill/finishing Prism's PM101, an acute care cardiovascular drug. HollisterStier is producing PM101 registration material for clinical trials and is supporting Prism's filing of an NDA. PM101 will be filled into vials and syringes.
Anthony Bonanzino, Ph.D., president and chief executive officer of HollisterStier, said, "HollisterStier is pleased to partner with Prism Pharmaceuticals on the development of this cardiovascular drug. HollisterStier's history of providing high quality service to our clients inevitably allows us to lower the development risk for companies like Prism. We provide a multifunctional team dedicated to solving their project goals quickly, which enables Prism to reduce the time to market."
Kathleen DeLawrence, vice president and chief operating officer of Prism Pharmaceuticals Inc., said, "We are pleased to be working with such an experienced contract manufacturer on our initial product development program. The team that HollisterStier has assembled to support our program is very experienced and committed to meeting our expectations for speed and excellence in execution."
Anthony Bonanzino, Ph.D., president and chief executive officer of HollisterStier, said, "HollisterStier is pleased to partner with Prism Pharmaceuticals on the development of this cardiovascular drug. HollisterStier's history of providing high quality service to our clients inevitably allows us to lower the development risk for companies like Prism. We provide a multifunctional team dedicated to solving their project goals quickly, which enables Prism to reduce the time to market."
Kathleen DeLawrence, vice president and chief operating officer of Prism Pharmaceuticals Inc., said, "We are pleased to be working with such an experienced contract manufacturer on our initial product development program. The team that HollisterStier has assembled to support our program is very experienced and committed to meeting our expectations for speed and excellence in execution."